Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979052 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
A Phase 2 study of Candidemia, sponsored by Radboud University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT04979052 is a Phase 2 study of Candidemia that is actively recruiting participants, run by Radboud University Medical Center. The registered enrollment target is 200 participants, below the 389-participant average among 8 other Candidemia trials with a reported enrollment target (49% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT04979052, a Phase 2 study of Candidemia, is actively recruiting participants, sponsored by Radboud University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Conditions Studied
Interventions
- DRUG Interferon Gamma-1B
Study Locations (6)
Other
- Klinikum Der Johann Wolfgang Von Goethe Universitaet - Frankfurt am Main
- Hellenic Institute for the Study of Sepsis (HISS) - Athens
- Universitatea de Medicina si Farmacie luliu Hatieganu - Cluj-Napoca
- Centre Hospitalier Universitaire Vaudois - Lausanne
North Carolina
- Duke University - Durham
Gelderland
- Radboudumc - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04979052
The ClinicalTrials.gov registry entry for NCT04979052 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 389-participant average among 8 other Candidemia trials with a reported enrollment target (49% lower). The listed sponsor is Radboud University Medical Center, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Candidemia appearing as the primary indexed condition, and to 1 intervention - of which Interferon Gamma-1B is the first listed.
NCT04979052 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, North Carolina, Gelderland.
Frequently Asked Questions
What is clinical trial NCT04979052 about?
NCT04979052 is a clinical study titled "Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia". A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
What is the current status of trial NCT04979052?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-03-31. Estimated completion is 2026-06-30.
What conditions does trial NCT04979052 study?
This clinical trial studies the following conditions: Candidemia.
What interventions are being tested in trial NCT04979052?
The interventions under investigation include: Interferon Gamma-1B (DRUG).
Who is sponsoring clinical trial NCT04979052?
This trial is sponsored by Radboud University Medical Center, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04979052 being conducted?
This trial has 6 study locations across North Carolina, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
COMPLETED · Phase 2
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.